NASDAQ$PCVX
Vaxcyte Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Vaxcyte reported Q3 2023 financial results and provided a business update.
Vaxcyte reported $1.4342 billion in cash, cash equivalents and investments as of September 30, 2023. The company's net loss was $92.7 million, compared to $57.9 million for the same period in 2022. VAX-24 adult Phase 3 program is expected to have topline data in 2025. VAX-31 Adult IND Application received FDA Clearance; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024.
- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24.
- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024.
- Advanced Ongoing VAX-24 Infant Phase 2 Study; Topline Data from Primary Immunization Series Expected by 2025.
- Expanded Collaboration with Lonza for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations.
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$0
Forward guidance
Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key upcoming milestones.
Tailwinds
- Meetings with the FDA regarding the Company’s CMC strategy to finalize the Company’s Phase 3 program and BLA requirements expected to occur through the first quarter of 2024.
- Topline safety, tolerability and immunogenicity data from the Phase 3 pivotal non-inferiority study in adults in 2025.
- Topline safety, tolerability and immunogenicity data from the primary three-dose immunization series of the infant Phase 2 study by 2025, followed by topline data from the booster dose approximately nine months later.
- Initiation of the Phase 1/2 study in the fourth quarter of 2023.
- Topline safety, tolerability and immunogenicity data from the Phase 1/2 study in adults in second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro